[Treatment Result of Neoadjuvant Endocrine Therapy in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer in Our Hospital].

To date, neoadjuvant endocrine therapy has shown the same rate of clinical objective response and breast-conserving surgery as neoadjuvant chemotherapy in postmenopausal patients with hormone receptor-positive breast cancer. Moreover, neoadjuvant endocrine therapy is recommended to the patients who are unable to tolerate side effects associated with chemotherapy or who are ineligible for immediate surgery because of their age and comorbidity. We discuss the result of neoadjuvant endocrine therapy in our hospital last 5 years. Nine patients underwent preoperative endocrine therapy between 2015 and 2019. Pathological examinations consisted 7 invasive ductal carcinomas and 2 mucinous carcinomas. The result of preoperative examinations was 7 partial response(PR), 1 complete response(CR), and 1 progress disease(PD). 3 months after initiation, all patients were examined by palpation and US. 6 months after initiation, all patients showed a partial response. These results suggest that neoadjuvant endocrine therapy allows downstaging of tumors and more minimally invasive surgery.